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ABSTRACT
Background: Evidence for medical interventions sometimes derives from data that are no longer up to date. These data can influence the out­
comes of meta­analyses, yet do not always reflect current clinical practice. We examined the age of the data used in meta­analyses contained with­
in systematic reviews of medical interventions, and investigated whether authors consider the age of these data in their interpretations.
Methods: From Issue 4, 2005, of the Cochrane Database of Systematic Reviews we randomly selected 10% of systematic reviews containing at
least 1 meta­analysis. From this sample we extracted 1 meta­analysis per primary outcome. We calculated the number of years between the study’s
publication and 2005 (the year that the systematic review was published), as well as the number of years between the study’s publication and the
year of the literature search conducted in the study. We assessed whether authors discussed the implications of including less recent data, and, for
systematic reviews containing meta­analyses of studies published before 1996, we calculated whether excluding the findings of those studies
changed the significance of the outcomes. We repeated these calculations and assessments for 22 systematic reviews containing meta­analyses
published in 6 high­impact general medical journals in 2005.
Results: For 157 meta­analyses (n = 1149 trials) published in 2005, the median year of the most recent literature search was 2003 (interquartile
range [IQR] 2002­04). Two­thirds of these meta­analyses (103/157, 66%) involved no trials published in the preceding 5 years (2001­05). Forty­
seven meta­analyses (30%) included no trials published in the preceding 10 years (1996­2005). In another 16 (10%), the statistical significance of
the outcomes would have been different had the studies been limited to those published between 1996 and 2005, although in some cases this
change in significance would have been due to loss of power. Only 12 (8%) of the meta­analyses discussed the potential implications of including
older studies. Among the 22 meta­analyses considered in high­impact general medical journals, 2 included no studies published in the 5 years pri­
or to the reference year (2005), and 18 included at least 1 study published before 1996. Only 4 meta­analyses discussed the implications of includ­
ing older studies.
Interpretation: In most systematic reviews containing meta­analyses of evidence for health care interventions, very recent studies are rare. Re­
searchers who conduct systematic reviews with meta­analyses, and clinicians who read the outcomes of these studies, should be made aware of
the potential implications of including less recent data.
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I
N THE SEARCH FOR BEST EVIDENCE, SYSTEMATIC
reviewers and clinicians alike often use studies con­
ducted a long time ago. What constitutes “a long
time” varies according to scientific topic, the interven­
tion under investigation, methodology, and differences
in study population. Whereas the findings of some trials
remain valid over time, others become less relevant
1­3 as
concomitant therapies and disease management
strategies change.
4­6
To date there has been little discussion of how often
older data are used in systematic reviews, or of the reli­
ability and relevance of these data, particularly in re­
gard to systematic reviews containing meta­analyses. To
our knowledge, no systematic assessment of the impact
of older data on the outcomes of meta­analyses within
systematic reviews exists.
In this study we sought to measure how recent is the
synthesized evidence in a representative random
sample of the Cochrane Database of Systematic Reviews
(CDSR), the largest and most comprehensive compila­
tion of systematic reviews on medical interventions.
7­9
We also evaluated whether authors of these studies dis­
cussed the age of trials included in their meta­analyses
and the implications of their inclusion. Finally, we
sought to determine whether meta­analyses published
in high­profile journals in 2005 were more likely to use
more recent data and if the authors discussed the im­
pact of using less recent data on their findings.
Methods
Selecting systematic reviews containing meta‐ana‐
lyses from the CDSR. We used Intercooled Stata 8.2
(College Station, Tex.) to randomly select 10% of the sys­
tematic reviews included in the CDSR, Issue 4 (2005),
keeping those that had not been subsequently with­
drawn and in which at least 1 meta­analysis had been
performed. Selecting only 1 meta­analysis per eligible se­
lectedsystematicreview, we assessedthe time since pub­
lication of the trials included in the meta­analysis and
determined whether the review authors discussed the
implications of including less recent trial data. When
more than 1 eligible meta­analysis was included in the
same systematic review, we retained the meta­analysis
that described the primary outcome as defined by the re­
view. If the review included meta­analyses for more
than 1 primary outcome and/or more than 1 comparis­
on of interventions, we retained the meta­analysis that
encompassed the greatest number of trials. In the case
of a tie, we chose the meta­analysis with the greatest cu­
mulative sample size. With further ties for a binary out­
come we then selected the meta­analysis with more
events. Whenever the same trials had been entered as 2
or more comparisons in the same meta­analysis, we
counted them as a single trial and calculated its total
sample size. Both authors reviewed the random sample
and selected relevant meta­analyses. Discrepancies
were resolved by consensus.
Data extraction and timing of publication. From each
selected meta­analysis, we extracted information on the
year of publication of each included trial, the number of
participants, and information to calculate the effect size
(odds ratio for binary outcomes, standardized or
weighted mean difference for continuous outcomes, as
specified in each review) and its variance.
Because some authors disseminate their trial results
in several articles and meeting abstracts, we consist­
ently used the publication year for the main article, as
selected by the Cochrane reviewers. We validated this
process by screening the articles and meeting abstracts
from a random sample of 50 trials included in our ana­
lyses.
For eligible trials in which the Cochrane reviewers
had not selected a specific article and year of publica­
tion or year for data retrieval, we selected the most re­
cent listed articles or abstracts of the trial; for those
studies with entirely unpublished data, we used the year
of the last literature search.
We also noted when the last literature search was
performed for the systematic review; where this inform­
ation was unavailable, we recorded the year of last
amendment.
Determining the timing of included studies. The
definition of an “older” study varies across medical spe­
cialty and from study to study. For operational pur­
poses, we used the last 5 years (2001­05), 10 years
(1996­2005) and 20 years (1986­2005) from the public­
ation year of the CDSR database as pre­specified cut­
offs.
Examining implications of including older trials. We
examined whether the authors of each selected system­
atic review discussed any implications relating to the
fact that some or all of the trials included in their meta­
analyses were older, and whether systematic reviews
discussing these implications had included, overall,
older trials than those that did not discuss any such is­
sues.
Sensitivity analyses. We conducted sensitivity analyses
addressing the 5­, 10­ and 20­year estimates using the
year of the literature search rather than the CDSR issue
date (2005) as a reference year. Using the latter reflects
how recent the evidence is for clinical practice at the
time of the CDSR issue publication, while using the year
of the literature search subtracts the time lag between
the literature review and its publication in 2005.Research Patsopolous
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We also assessed the impact on meta­analyses of in­
cluding only studies published in the last decade (1996­
2005). Specifically, we recorded how many meta­ana­
lyses included such studies, and how many would have
reached different inferences for the statistical signific­
ance of the summary effect (p < 0.05 or p ≥ 0.05) had
only these studies been included.
Examining systematic reviews published in major
medical journals. We also assessed systematic reviews
containing meta­analyses published in 6 major medical
journals (New England Journal of Medicine, Journal of
the American Medical Association, The Lancet, British
Medical Journal, Annals of Internal Medicine and PLoS
Medicine) between July and December 2005. The ex­
amined journals publish systematic reviews of broad
medical interest, thus reducing the risk of evaluating
topics on few specialties. We followed a protocol similar
to that described above for the selection of meta­ana­
lyses from systematic reviews in the CDSR.
The year (late 2005) was chosen to be the same as
the issue of CDSR that we evaluated. We included only
systematic reviews containing at least 1 meta­analysis.
When more than 1 meta­analysis of interventions
and/or outcomes existed, we followed the same proced­
ure as for the CDSR systematic reviews to select 1 meta­
analysis per article. From each eligible meta­analysis we
extracted the year of the literature search, the number
of synthesized trials, and the number of trials published
in the last 5 years (2001­05), 10 years (1996­2005) and
20 years (1986­2005). We did not collect information
on sample size per trial and effect size because these
were not sufficiently standardized to allow consistent
analyses. Otherwise, we evaluated the proportion of re­
cent data and whether the implications of including
older data were discussed by review authors, as de­
scribed for the analysis of systematic reviews from the
CDSR.
Statistical analysis. Summary results were calculated
using the DerSimonian and Laird random effects mod­
el
10 allowing for variability across trials. Comparison of
the publication years of the synthesized trials years was
made with Mann­Whitney U test. P values are two­
tailed. Analyses were conducted with Intercooled Stata
8.2 (College Station, Tex.).
Results
Systematic reviews and meta‐analyses selected from
the CDSR. We randomly sampled 165 of 1651 eligible
systematic reviews from the CDSR (Fig. 1). Of these, 8
were excluded (6 had been withdrawn, and 2 contained
no quantitative synthesis). Of the remaining 157 system­
atic reviews, the selected outcomes were binary in 133
meta­analyses and continuous in 24 meta­analyses.
(See Online Appendix 1 for a complete list of the CDSR
systematic reviews and meta­analyses included in this
study.)
Overall, 1149 trials (1 650 701 participants) were in­
cluded in the meta­analyses for the primary outcomes
for included systematic reviews. There was a median of
5 trials included in each meta­analysis (IQR 3­7) and of
617 (IQR 227­1711) participants.
The median year (IQR) of the last literature search
across the 157 systematic reviews was 2003 (2002­04).
There were 19 reviews whose date of last search was in
2005, and 43 whose last search was in 2004. In another
11 reviews the last year of literature search was before
2000, and in 6 of these the most recent included trial
had been published at least 3 years earlier. The repres­
entation of recent data increased slightly when the ref­
erence was shifted to the year of the last literature
search rather than 2005 (i.e., the year of publication of
the systematic review).
Of the random sample of 50 trials (of the total 1149
trials encompassed by the 157 meta­analyses included
in our review) 44 had the same publication year; for 1
trial, the publication years spanned 2 consecutive years,
for another, publication years spanned 3 consecutive
years, and in 4 trials publication years spanned a longer
period.
Overall, few meta­analyses consisted of data from
trials published in the 5 years prior to the publication in
the CDSR (2005), and only a quarter of the trials they
synthesized had been published within 5 years of the
last literature search (Table 1). One­third of meta­ana­
lyses included data from trials that had been published
in the last 10 years, and two­thirds had been published
within 10 years of the literature search. A 20­year win­
dow usually captured most or all of the trials that con­
tributed data to the included meta­analyses.
Almost one­third (30%, 47/157) of meta­analyses in­
cluded no trials published in the period 1996­2005,
while only 2 meta­analyses (1%, 2/157) consisted en­
tirely of data from trials published in the same period
(Table 2). The respective proportions were 18%
(29/157) and 55% (87/157) for a 10­year time frame
from the year of the systematic reviews’ last literature
search.
Of the 157 meta­analyses surveyed, 47 included only
trials published before 1996. Of the remaining 110
meta­analyses, 21 included trials that were all published
in the last decade. Among the 89 meta­analyses that in­
cluded trials published in the last decade and earlier,
exclusion of the data published before 1996 changed the
level of statistical significance of the summary effects in
16; in 9 cases the summary effects became non­statistic­
ally significant, and the opposite change was seen in 7
cases. The summary odds ratio for these 16 meta­ana­
lyses changed by a median of 23% (IQR 9%­41%).Research Patsopolous
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Discussion of implications of including less recent
studies. Only 12 of 157 systematic reviews (8%) dis­
cussed the possible implications of including older tri­
als. These included meta­analyses related to pregnancy
and neonatal medicine (4), neuropsychiatric disease
(4), pulmonary disease (2), diabetes mellitus (1) and
chemotherapy for bladder cancer (1). The authors of 2
of these reviews concluded that the year of publication
was unlikely to matter; 10 reviews expressed some con­
cern, and 2 clearly stated the importance of revisiting
the clinical question with new trials. Trials included in
these 12 meta­analyses were significantly older than
those included in the other 145 meta­analyses that did
not discuss the age of the trials (p = 0.003).
Most of the systematic reviews that included trials
published before 1986 (61/70) and 124 of the 136 sys­
tematic reviews that included trials published before
1996 did not discuss the age of the included trials.
Systematic reviews published in major medical
journals. Twenty­five systematic reviews containing
meta­analyses were published in 2005 in the 6 high­im­
pact general medical journals, of which 22 had data
available on the publication year of the synthesized tri­
als (Online Appendix 2). The median (IQR) of the literat­
ure search year, reported in 15 of the 22 reviews, and
the number of synthesized studies were 2005 (2004­
05) and 11 (8­15), respectively. Median proportions
(IQR) of trials published in the last 5, 10, or 20 years
since 2005 were 39 (17­50), 68 (45­90), and 100 (92­
100), respectively. Two meta­analyses had no trials
published in the previous 5 years (2001­05), while all
had at least 1 trial published in the last decade (1996­
2005). Eighteen meta­analyses included at least 1 study
published before 1996.
Four systematic reviews discussed the implications
of including less recent data in their meta­analyses. One
of these also performed a sensitivity analysis that in­
cluded only trials published in the last decade. The me­
dian year of publication for the trials included in these 4
systematic reviews showed no statistically significant
difference than in the other 19, which did not discuss
the age of the trials (p = 0.46). Overall, 7 of the 9 sys­
tematic reviews that included trials published before
1986 did not discuss the implications of including less
recent trials.
Discussion
Our analysis suggests that, even with the best inten­
tions, evidence­based medicine has to rely on less re­
cent evidence. Even when results
were corrected for the year of the
last literature search, few systematic
reviews containing meta­analyses in
the CDSR included trials published
in the preceding 5 years. Almost a
third of these included no trials
published in the last decade, and in
another 10% the statistical signific­
ance of the result related to the
study primary outcome would have
been different had the data been
limited to the last decade. Most of
the systematic reviews did not ad­
dress the implications of including
less recent data.
Meta­analyses published in
high­profile peer­reviewed journals
tend to address newer interventions
than the average CDSR review. Ac­
cordingly, almost all of them in­
cluded some trials published in the
last 5 years, and all of them in­
cluded some trials published in the
last decade. Nevertheless, even in
these meta­analyses, the large ma­
jority also included 1 or more older
trials, and very few discussed the
implications of including older evid­
ence.
Figure 1. Flow diagram of selection of systemic reviews and meta‐analysesResearch Patsopolous
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Typically, the lack of recent evidence did not result
from the CDSR systematic reviews being out of date; in
fact, the majority of systematic reviews that we analyzed
had been updated in the last 2 years. Nonetheless, few
systematic reviews discussed the implications of the
time of publication on the relevance of the evidence.
Evidence should not be undervalued simply because
of its age. The amount of data, regardless of year of pub­
lication, is limited for most health care topics,
11­13 and
we do not have the luxury of discarding trials simply be­
cause of their calendar year. In the case of topics for
which well­designed old clinical trials are still relevant
and conclusive, it is imprudent, and even unethical, to
conduct new trials.
Occasionally, earlier published results may differ
from those reported in later publications.
14­16 This may
reflect bias,
17­19 time­dependent efficacy (e.g., when the
treatment benefit decreases with longer follow­up),
20
quality differences,
21,22 or chance. For example, in the
case of vitamin E supplementation for prevention of
morbidity and mortality in preterm infants, the review
authors suggest caution in interpreting and applying
current evidence. The available data span over a decade
(1991­2002), a period in which many advances were
made in the field of preterm care.
23 However, one can­
not generalize. Less recent trials are not necessarily of
worse quality,
24,25 smaller,
26 or less externally valid
4,5
than newer ones.
2 Each topic needs a careful case­by­
case scrutiny of whether the available evidence is relev­
ant to current practice. The availability of evidence is
sometimes further restricted by the lack of standardized
outcomes across trials. Selective reporting of “positive”
outcome results is an added threat.
27­29
Some limitations should be discussed. Although we
used a standardized approach to select the year of pub­
lication, a trial may be in progress for many years be­
fore any results are published. Most trials do not specify
when they started and completed enrolment and fol­
low­up. Efficacy trials may take 3 to 10 or more years
from the start of enrolment to publication.
17 Therefore,
the proportion of recently conducted trials is likely even
smaller than what we report on the basis of publication
year.
Second, we used the CDSR for our primary analyses
because it is widely considered the most all­encom­
passing and up­to­date source for current evidence on
health care interventions. However, even the CDSR rep­
resents work in progress, and it does not capture all in­
terventions.
30 Furthermore, some review authors may
choose to exclude, a priori, less recent studies, espe­
cially in fast­moving areas of research, by restricting
search years or requiring the reporting of methodolo­
gical quality characteristics.
Our evaluation of systematic reviews published in
medical journals was unavoidably more restricted, since
some information (such as primary outcome) is not
standardized and is readily available in the same detail
as in the CDSR systematic reviews.Research Patsopolous
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We should also caution that decision­making based
on nominal statistical significance is precarious.
31,32 A
change in statistical significance does not mean that the
estimated effect size is altered beyond chance. Neither
can it be attributed with certainty to less recent studies,
since many underlying factors (including chance alone)
contribute to the uncertainty of the effect estimate. Giv­
en that most meta­analyses had very limited data over­
all, there was large uncertainty in the estimated effect
size in recent compared with less recent published data.
Direct comparisons of recent against less recent data
would be underpowered to show even major differences
in effect sizes in these meta­analyses.
However, some empirical evidence suggests that, in
some fields, smaller treatment effects may be en­
countered in more recent trials than in earlier re­
search.
1,14­16,33 In the present evaluation, in the
meta­analyses in which the formal statistical signific­
ance status of the summary effect changed with the ex­
clusion of less recent data, the median change in the
odds ratio was also 23%. This is a considerable change,
given that most medical interventions have modest ef­
fects.
Acknowledging these caveats, our survey suggests
that even though the CDSR reviews are frequently up­
dated, evidence from very recently published studies for
most health care interventions is scant. Although less re­
cent studies should not be discarded, clinicians should
interpret medical evidence with attention to the applic­
ability and relevance of these studies to current clinical
practice. If evidence on a specific topic is considered to
be outdated or missing, and the review question re­
mains salient, the scientific community should be sensit­
ized toward conducting relevant targeted studies.
Contributors: JPAI had the original idea for this study, and
both authors developed the protocol. NAP organized the
databases and performed the analyses with help from JPAI.
Both authors interpreted the data and the analyses and both
wrote the manuscript.
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